Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYEZ5J)

• Drug Name: Romilkimab Drug Info
• Synonyms: SAR156597

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMYEZ5J

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[3]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[5]
Tepoxalin	DMVS61L	Asthma	CA23	Phase 2	[6]
IL-4R	DMYEGRH	N. A.	N. A.	Phase 2	[7]
Pascolizumab	DMU3XJP	Asthma	CA23	Phase 2	[5]
PF-07264660	DM0GI2H	Atopic dermatitis	EA80	Phase 1	[8]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[8]

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[9]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[5]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[3]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[10]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[5]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[11]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[12]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[11]
CNTO-5825	DMF8WAT	Allergic asthma	CA23.0	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Inhibitor	[2]
Interleukin-4 (IL4)	TTLGTKB	IL4_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR). U.S. National Institutes of Health.
• [2] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [3] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [4] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [5] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [6] Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
• [7] Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
• [8] Clinical pipeline report, company report or official report of Pfizer
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [11] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [12] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
• [13] Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.